Pfizer Expects 2024 Sales Of $59.5B-$62.5B Compared To Prior Guidance Of $58.5B-$61.5B And Consensus Of $60.668B
Portfolio Pulse from Benzinga Newsdesk
Pfizer has updated its 2024 sales guidance to a range of $59.5 billion to $62.5 billion, compared to the previous guidance of $58.5 billion to $61.5 billion and the consensus estimate of $60.668 billion.
July 30, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has raised its 2024 sales guidance to $59.5 billion to $62.5 billion, which is higher than both its previous guidance and the consensus estimate. This positive revision indicates stronger expected performance.
The increase in sales guidance suggests that Pfizer expects better-than-anticipated performance in 2024. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100